Designing Clinical Trials: Balancing Data Collection and Patient Burden

Steven Zelenkofske DO currently is principal consultant for SLZ consulting LLC, board director for Dinaqor AG and Cadrenal Therapeutics and chief strategy officer for Dinaqor AG. Dr Zelenkofske brings more than 20 years of industry development experience, most recently as Chief Medical Officer of SwanBio therapeutics, a gene therapy company specializing in neurodegenerative diseases. Previously he served as Chief Medical Officer of Achillion Pharmaceuticals and Regado Biosciences. He has also held leadership positions at Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. Dr Zelenkofske has been responsible for multiple NDA filings and has worked across multiple therapeutic areas including cardiovascular, metabolic diseases, diabetes, nephrology, hematology, immunology and neurology. Dr Zelenkofske completed his residency training at Philadelphia College of Osteopathic Medicine, followed by fellowships in cardiology and electrophysiology at The Graduate Hospital, Philadelphia, and St Luke’s Hospital, New York, respectively. He is a graduate of Emory University, where he also earned a Master of Science degree in immunopharmacology. He earned his Doctor of Osteopathy from Philadelphia College of Osteopathic Medicine. He is a fellow of the American College of Cardiology, the American College of Chest Physicians, and the American College of Osteopathic Internists.

Judith Ng-Cashin, M.D., has served as Chief Medical Officer for Novotech since 2023. Previously, she held key senior executive positions, including CMO and CSO roles, at Eagle Pharmaceuticals, Inc., Syneos Health, AoBiome Therapeutics, and INC Research. Dr. Ng-Cashin also serves on the Scientific Advisory Board for Revibe Technologies.

TBA

Professor Bertil Lindmark is the CMO of Vicore Pharma since 2024 and has a long career within the pharmaceutical industry with deep expertise within respiratory and inflammatory diseases. Bertil has held global roles within AstraZeneca, leading the development of global brands like Pulmicort and Symbicort. He was the Head of Research and Development at Almirall, leading the development of the second to market inhaled long acting antimuscarinic, aclidinium bromide. Bertil also held CMO roles in biotech companies, ASLAN Pharmaceuticals, eTheRNA Immunotherapies, and Galecto, where his leadership played a crucial role in driving innovation and advancing pharmaceutical development of both oncology compounds, liver disease compounds and IPF directed therapies. Bertil Lindmark is Professor Emeritus at the University of Gothenburg, chairs the scientific committee at the Board of ALK, and is the Chairman of the Board at Aqilion.

Erik has 10+ years of pharma experience at Novartis, IQVIA, the Swiss Army and holds an MMedSc in Health Informatics from Karolinska Institute. After years of manually compiling trial data for sponsors, Erik co-founded Rivia to solve the invisible barrier to breakthroughs: fragmented and cumbersome trials through AI-driven analytics.